Using gold nanoparticles to detect single-nucleotide polymorphisms: toward liquid biopsy

• María Sanromán Iglesias and
• Marek Grzelczak

Beilstein J. Nanotechnol. 2020, 11, 263–284, doi:10.3762/bjnano.11.20

• possibility of detecting genetic mutations rapidly in physiological media through liquid biopsy has attracted the attention within the materials science community. The physical properties of nanoparticles combined with robust transduction methods ensure an improved sensitivity and specificity of a given assay

• simple blood test, setting thus a milestone of “liquid biopsy”. Liquid biopsy has the potential to accelerate the early cancer diagnosis by the detection of biomolecules such as cell-fee DNA directly in blood samples. Currently, the development of liquid biopsies is directly linked to the state-of-the

• techniques are without parallel in the analysis of genetic material and the detection of mutations, they require an operation by specialized personnel in large infrastructures such as hospitals or research centers. The democratization of liquid biopsy and therefore the advancement of personal medicine needs

Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection

• Dinusha N. Udukala,
• Hongwang Wang,
• Sebastian O. Wendel,
• Aruni P. Malalasekera,
• Thilani N. Samarakoon,
• Asanka S. Yapa,
• Gayani Abayaweera,
• Matthew T. Basel,
• Pamela Maynez,
• Raquel Ortega,
• Yubisela Toledo,
• Leonie Bossmann,
• Colette Robinson,
• Katharine E. Janik,
• Olga B. Koper,
• Ping Li,
• Massoud Motamedi,
• Daniel A. Higgins,
• Gary Gadbury,
• Gaohong Zhu,
• Deryl L. Troyer and
• Stefan H. Bossmann

Beilstein J. Nanotechnol. 2016, 7, 364–373, doi:10.3762/bjnano.7.33

• . Keywords: biophotonics; breast cancer; iron/iron oxide nanoparticle; liquid biopsy; nanodiagnostics detection; nanomedicine; sub-femtomolar limit of detection; Introduction We have detected stage I breast cancer in human patients with statistical significance by means of a simple serum test using highly

• -care diagnostics, it is still more than minimally invasive, because the nanoworms have to be given intravenously. An ideal “liquid biopsy” [30] will require only the drawing of a simple blood sample to detect cancer, without introducing a reagent to the patient’s body first. In this report, we would

• always when testing biomarkers, the selection process of the required biospecimens is crucial. Therefore, our next steps will consist in testing our liquid biopsy approach with significantly larger group sizes of stage 0 and I breast cancer patients. Methods Nanoplatform synthesis The synthesis and